Please insert the attached Sequence Listing immediately before the Claims.

IN THE CLAIMS

Please amend the claims as follows (including Claims 35-62 attached to the International Preliminary Examination Report):

Cancel claims 1-20 without prejudice or disclaimer to the subject matter thereof.

Amend Claims 23, 28, 31-34, 41, 44-45, 52, 55-56, 58, 60 and 62 as follows:

23. (Amended) The pharmaceutical composition according to claim 21 wherein said peptide analogue has the formula (SEQ ID N° : 1) :

A1-A2-A3-A4-A5-A6-A7-A8-Pro-Z(A)

in which :

- A1 is pGlu ; D-pGlu ; Sar ; AcSar ; Pro or a derivative thereof ; Ser ; D-Ser ; Ac-D-Ser ; Thr ; D-Thr ; Ac-D-Thr ; or an aromatic D-amino acid which may be acylated ;
- A2 is a direct bond ; His ; or an aromatic D-amino acid;
- A3 is an aromatic L- or D-amino acid;
- A4 is Ala, Ser, D-Ser, MeSer, Ser(OBu^t), Ser(OBzl) or Thr;

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
612 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155

- A5 is an aromatic L-amino acid ; or a basic L- or D-amino acid;

- A6 is Gly ; (S)-spirolactam-Pro ; D-Pro ; D-Ser ; D-Thr ; D-Cys ; D-Met ; D-Pen ; D-(S-Me)Pen ; D-(S-Et)Pen ; D-Ser(OBu^t) ; D-Asp(OBu^t) ; D-Glu(OBu^t) ; D-Thr(OBu^t) ; D-Cys(OBu^t) ; D-Ser(OR_1) where R_1 is a sugar moiety ; an aza-amino acid ; D-His which may be substituted on the imidazole ring by a (C_1-C_6)alkyl, a (C_2-C_7)acyl or a benzyl group ; an aliphatic D-amino acid with a (C_1-C_8)alkyl or a (C_3-C_6)cycloalkyl side chain ; an aromatic D-amino acid ; D-cyclohexadienyl-Gly ; D-perhydronaphthyl-Ala ; D-perhydrodiphenyl-Ala ; or a basic L- or D-amino acid;

- A7 is a linear, branched or cyclic aliphatic L-amino acid of 3 to 20 carbon atoms which may be N-alpha-substituted by a (C_1-C_4)alkyl group optionally substituted by one or several fluorine atoms;

- A8 is a basic L- or D-amino acid ;

- Z is $GlyNH_2$; D-$AlaNH_2$; aza$GlyNH_2$; or a group -NHR_2 where R_2 is a (C_1-C_4)alkyl which may be substituted by an hydroxy or one or several fluorine atoms ; a (C_3-C_6)cycloalkyl ; or a

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
612 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155

A2

heterocyclic radical selected from morpholinyl, pyrrolidinyl and piperidyl.

28. (Amended) The pharmaceutical composition according to claim 24 wherein the peptide analogue is selected from the group consisting of leuprorelin, [Npg^7]-leuprorelin, triptorelin, [Npg^7]-triptorelin, goserelin, [Npg^7]-goserelin, buserelin and [Npg^7]-buserelin.

A3

31. (Amended) The pharmaceutical composition according to claim 29 wherein the peptide analogue is selected from the group consisting of antide, [Npg^7]-antide, cetrorelix, [Npg^7]-cetrorelix, abarelix and [Npg^7]-abarelix.

A4

32. (Amended) The pharmaceutical composition according to claim 21 wherein the α-cyclodextrin derivative is selected from the group consisting of methylated α-cyclodextrin, hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin, carboxy-methylated α-cyclodextrin and phosphated α-cyclodextrin.

33. (Amended) The pharmaceutical composition according to claim 32 wherein the α-cyclodextrin derivative is hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin.

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
612 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155

34. (Amended) The pharmaceutical composition according to claim 21 which further comprises a compound selected from the group consisting of a protease inhibitor, an absorption enhancer, and mixtures thereof.

41. (Amended) The method according to claim 37 wherein the peptide analogue is selected from the group consisting of leuprorelin, [Npg^7]-leuprorelin, triptorelin, [Npg^7]-triptorelin, goserelin, [Npg^7]-goserelin, buserelin and [Npg^7]-buserelin.

44. (Amended) The method according to claim 42 wherein the peptide analogue is selected from the group consisting of antide, [Npg^7]-antide, cetrorelix, [Npg^7]-cetrorelix, abarelix and [Npg^7]-abarelix.

45. (Amended) The method according to claim 35 wherein the α-cyclodextrin derivative is selected from the group consisting of methylated α-cyclodextrin, hexakis(2,3,6-tri-O-methyl)- α-cyclodextrin, carboxymethylated α-cyclodextrin and phosphated α-cyclodextrin.

52. (Amended) The method according to claim 48 wherein the peptide analogue is selected from the group consisting of

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
612 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155

leuprorelin, [Npg^7]-leuprorelin, triptorelin, [Npg^7]-triptorelin, goserelin, [Npg^7]-goserelin, buserelin and [Npg^7]-buserelin.

55. (Amended) The method according to claim 53 wherein the peptide analogue is selected from the group consisting of antide, [Npg^7]-antide, cetrorelix, [Npg^7]-cetrorelix, abarelix and [Npg^7]-abarelix.

56. (Amended) The method according to claim 47 wherein the α-cyclodextrin derivative is selected from the group consisting of methylated α-cyclodextrin, hexakis(2,3,6-tri-O-methyl)- α-cyclodextrin, carboxymethylated α-cyclodextrin and phosphated α-cyclodextrin.

58. (Amended) The method according to claim 47 for the treatment or prevention of breast cancer.

60. (Amended) The method according to claim 47 for the treatment or prevention of prostate cancer or benign prostatic hypertrophy.

62. (Amended) The method according to claim 47 wherein the peptide analogue is delivered to the gastrointestinal tract of the patient.

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
612 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155

Please add the following new claims:

--63. (New) The pharmaceutical composition according to claim 28 wherein the α-cyclodextrin derivative is selected from the group consisting of methylated α-cyclodextrin, hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin, carboxy-methylated α-cyclodextrin and phosphated α-cyclodextrin.

64. (New) The pharmaceutical composition according to claim 28 comprising α-cyclodextrin or hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin.

65. (New) The pharmaceutical composition according to claim 64 wherein the peptide analogue is leuprorelin.

66. (New) The pharmaceutical composition according to claim 64 wherein the peptide analogue is [Npg^7]-leuprorelin.

67. (New) The method according to claim 41 wherein the α-cyclodextrin derivative is selected from the group consisting of methylated α-cyclodextrin, hexakis(2,3,6-tri-O-methyl)- α-cyclodextrin, carboxymethylated α-cyclodextrin and phosphated α-cyclodextrin.

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
612 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155

68. (New) The method according to claim 67 wherein the α-cyclodextrin derivative is hexakis(2,3,6-tri-O-methyl)- α-cyclodextrin.

69. (New) The method according to claim 35, which comprises orally administering a therapeutically effective amount of leuprorelin in combination with α-cyclodextrin or hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin.

A1 cont

70. (New) The method according to claim 35, which comprises orally administering a therapeutically effective amount of [Npg^7]-leuprorelin in combination with α-cyclodextrin or hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin.

71. (New) The method according to claim 52 wherein the α-cyclodextrin derivative is selected from the group consisting of methylated α-cyclodextrin, hexakis(2,3,6-tri-O-methyl)- α-cyclodextrin, carboxymethylated α-cyclodextrin and phosphated α-cyclodextrin.

72. (New) The method according to claim 71 wherein the α-cyclodextrin derivative is hexakis(2,3,6-tri-O-methyl)- α-cyclodextrin.

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
612 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155

73. (New) The method according to claim 47, which comprises orally administering a therapeutically effective amount of leuprorelin in combination with α-cyclodextrin or hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin.

74. (New) The method according to claim 47, which comprises orally administering a therapeutically effective amount of [Npg^7]-leuprorelin in combination with α-cyclodextrin or hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin.

75. (New) The method according to claim 62 wherein the α-cyclodextrin derivative is selected from the group consisting of methylated α-cyclodextrin, hexakis(2,3,6-tri-O-methyl)- α-cyclodextrin, carboxymethylated α-cyclodextrin and phosphated α-cyclodextrin.

76. (New) The method according to claim 71 wherein the α-cyclodextrin derivative is hexakis(2,3,6-tri-O-methyl)- α-cyclodextrin.

77. (New) The method according to claim 76 wherein the peptide analogue is leuprorelin.

78. (New) The method according to claim 76 wherein the peptide analogue is [Npg^7]-leuprorelin.--

LAW OFFICES
DENNISON, SCHEINER, SCHULTZ & WAKEMAN
6 2 CRYSTAL SQUARE 4
1745 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202-3417
703 412-1155